Study of the antibiotic resistance profile of Nosocomial Infection in patients infected with COVID- 19

Abstract

Nosocomial infections have been impacted by the COVID-19 pandemic in a complicated and diverse way. Although strict infection control protocols have led to the decline of certain HAIs, the overwhelming strain on healthcare systems and the growing use of invasive devices in COVID-19 therapy have made other forms of HAIs more prevalent. Furthermore, the pandemic has brought attention to how crucial it is to maintain strict infection control procedures and constant watchfulness in order to prevent HAIs.

Materials and Methods: Susceptibility profile and identification of the infection Pseudomonas aeruginosa and Acinetobacter baumannii isolates collected in different hospital services were performed by disc diffusion methods according to the CLSI/EUCAST guidelines, and API 20E, respectively.

The research materials were collected at the different hospital resuscitations from patients undergoing treatment for a long time who were resistant to antibiotics. As the results showed, Pseudomonas aeruginosa has the highest resistance to meropenem, ceftazidim, ciproflofloxacin, levofloxacin, and imipenem (100%), as well as resistance to Aztreonam, cefepime, and  tobramycin (80%), and  relatively low  resistance was  detected to  amikacin (20%). Acinetobacter baumannii showed the highest resistance to  meropenem, trimethoprim/sulfamethoxazole, tobramycin, ciproflofloxacin, levofloxacin, gentamycin, imipenem, and amikacin (100%). As research has shown, the number of effective antibiotics is gradually decreasing